Bevacizumab biosimilar - Alphamab/R-Pharm

Drug Profile

Bevacizumab biosimilar - Alphamab/R-Pharm

Alternative Names: Avastin biosimilar - Alphamab/R-Pharm; RPH-001

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alphamab; R-Pharm
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cancer

Most Recent Events

  • 26 Jul 2017 Phase-I development is ongoing in China
  • 26 Jul 2017 Phase-III development is ongoing in Russia and Turkey
  • 03 May 2017 TRPHARM plans a phase I trial in Healthy volunteers (NCT03131700)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top